Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient for p53Ser46 phosphorylation

The p53 tumor suppressor protein plays key roles in protecting cells from tumorigenesis. Phosphorylation of p53 at Ser46 (p53Ser46) is considered to be a crucial modification regulating p53- mediated apoptosis. Because the activity of p53 is impaired in most human cancers, restoration of wild-type p...

Full description

Saved in:
Bibliographic Details
Main Authors: Teng, Ma, Yamada, Shumpei, Ichwan, Solachuddin J. A., Ohtani, Kiyoshi, Otsu, Megumi, Ikeda, Masa-Aki
Format: Article
Language:English
Published: ELSEVIER 2012
Subjects:
Online Access:http://irep.iium.edu.my/13889/1/Inability_of_p53-reactivating_compounds_Nutlin-3_and_RITA.pdf
http://irep.iium.edu.my/13889/
http://www.sciencedirect.com/science/article/pii/S0006291X11022029
http://dx.doi.org/10.1016/j.bbrc.2011.11.161
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Islam Antarabangsa Malaysia
Language: English
Description
Summary:The p53 tumor suppressor protein plays key roles in protecting cells from tumorigenesis. Phosphorylation of p53 at Ser46 (p53Ser46) is considered to be a crucial modification regulating p53- mediated apoptosis. Because the activity of p53 is impaired in most human cancers, restoration of wild-type p53 (wt-p53) function by its gene transfer or by p53-reactivating small molecules has been extensively investigated. The p53-reactivating compounds Nutlin-3 and RITA activate p53 without genotoxic stress by antagonizing the action of its negative regulator Mdm2. Although controversial, Nutlin-3 was shown to induce p53-mediated apoptosis in a manner independent of p53 phosphorylation. Recently, RITA was shown to induce apoptosis by promoting p53Ser46 phosphorylation. Here we examined whether Nutlin-3 and RITA can overcome resistance to p53- mediated apoptosis in p53-resistant tumor cell lines lacking the ability to phosphorylate p53Ser46. We show that Nutlin-3 did not rescue the apoptotic defect of a Ser46 phosphorylation-defective p53 mutant in p53-sensitive tumor cells, and that RITA neither restored p53Ser46 phosphorylation nor induced apoptosis in p53Ser46 phosphorylation-deficient cells retaining wt-p53. Furthermore, treatment of Nutlin-3 or RITA, together with adenoviral p53 gene transfer, also failed to induce apoptosis in p53Ser46 phosphorylation-deficient cells either expressing or lacking wt-p53. These results indicate that Nutlin-3 and RITA are unable to induce p53-mediated apoptosis in the absence of p53Ser46 phosphorylation. Thus, the dysregulation of this phosphorylation in tumor cells may be a critical factor that limits the efficacy of these p53-based cancer therapies.